A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial
HPB — Watanabe G, Mise Y, Oba M, et al. | February 10, 2022
Via this multicenter phase II trial, researchers sought to ascertain the efficacy and safety of bevacizumab plus mFOLFOX6 for patients with advanced colorectal liver metastases (CRLMs) harboring mutant-type KRAS.
Researchers performed evaluation of surgical indication every 4 cycles of bevacizumab plus mFOLFOX6 among patients with advanced CRLMs (tumor number of ≥5 and/or technically unresectable) harboring mutant-type KRAS.
Among 29 registered patients from six centers, complete and partial responses were observed at the rates of 0% and 62.1%, respectively.
There were 19 and 1 patient who received R0 and R1 resections, respectively (R0 resection rate: 65.5%).
Overall findings suggest achievement of a high R0 resection rate for advanced CRLMs harboring mutant-type KRAS by using bevacizumab plus mFOLFOX6, resulting in favorable survival.
Read the full article on HPB